Multidisciplinary management of nonresectable hepatocellular carcinoma

Oncology

Volumn 81, Issue SUPPL. 1, 2011, Pages 134-140

  Park, Hee Chul ^a   Seong, Jinsil ^b   Tanaka, Masatoshi ^e   Zeng, Zhao Chong ^f   Lim, Ho Yeong ^a   Guan, Sheng ^g   Bae, Si Hyun ^c   Tak, Won Young ^d  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Kyungpook National University School of Medicine   (South Korea)

^e KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f FUDAN UNIVERSITY   (China)

^g ZHENGZHOU UNIVERSITY   (China)

Author keywords

Hepatitis B virus; Hepatocellular carcinoma, nonresectable; Multidisciplinary approach

Indexed keywords

AMINO ACID; ANTIVIRUS AGENT; DOXORUBICIN; SORAFENIB;

ADVANCED CANCER; ANTIVIRAL THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CHEMOEMBOLIZATION; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DISEASE CLASSIFICATION; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; NUTRITIONAL SUPPORT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SPLENECTOMY; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; HEPATITIS B; HUMANS; LIVER NEOPLASMS; PYRIDINES; TREATMENT OUTCOME;

EID: 84855333600     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000333276     Document Type: Review

References (40)

1. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J: Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference - European Association for the Study of the Liver. J Hepatol 2001;35:421-430. (Pubitemid 32844200)
2. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236. (Pubitemid 43112690)
3. Kudo M, Okanoue T: Management of hepatocellular carcinoma in Japan: consensusbased clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007;72(suppl 1):2-15. (Pubitemid 350256660)
4. Korean Liver Cancer Study Group and National Cancer Center, Korea: Practice guidelines for management of hepatocellular carcinoma 2009 (in Korean). Korean J Hepatol 2009;15:391-423.
5. Kokudo N, Makuuchi M: Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines. J Gastroenterol 2009;44(suppl 19):119-121.
6. Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, Yamashita T, Kokudo N, Tanaka M, Takayama T, Kudo M: Management of hepatocellular carcinoma: report of consensus meeting in the 45th annual meeting of the Japan Society of Hepatology (2009). Hepatol Res 2010;40:667-685.
7. Forner A, Reig ME, de Lope CR, Bruix J: Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010;30:61-74.
8. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK: Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-474.
9. Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, Poon R, Schwartz L, Tepper J, Yao F, Haller D, Mooney M, Venook A: Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 2010;28:3994-4005.
10. Ueno S, Tanabe G, Nuruki K, Hamanoue M, Komorizono Y, Oketani M, Hokotate H, Inoue H, Baba Y, Imamura Y, Aikou T: Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis. Hepatol Res 2002;24:395-403. (Pubitemid 36002129)
11. Kudo M: Real practice of hepatocellular carcinoma in Japan: conclusions of the Japan Society of Hepatology 2009 Kobe Congress. Oncology 2010;78(suppl 1):180-188.
12. Koda M, Murawaki Y, Mitsuda A, Oyama K, Okamoto K, Idobe Y, Suou T, Kawasaki H: Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study. Cancer 2001;92:1516-1524. (Pubitemid 32947837)
13. Lencioni R, Cioni D, Donati F, Bartolozzi C: Combination of interventional therapies in hepatocellular carcinoma. Hepatogastroenterology 2001;48:8-14. (Pubitemid 32226057)
14. Kitamoto M, Imagawa M, Yamada H, Watanabe C, Sumioka M, Satoh O, Shimamoto M, Kodama M, Kimura S, Kishimoto K, Okamoto Y, Fukuda Y, Dohi K: Radiofrequency ablation in the treatment of small hepatocellular carcinomas: comparison of the radiofrequency effect with and without chemoembolization. AJR Am J Roentgenol 2003;181:997-1003. (Pubitemid 37151780)
15. Qian J, Feng GS, Vogl T: Combined interventional therapies of hepatocellular carcinoma. World J Gastroenterol 2003;9:1885-1891. (Pubitemid 37168406)
16. Jang JW, Park YM, Bae SH, Choi JY, Yoon SK, Chang UI, Nam SW, Kim BS: Therapeutic efficacy of multimodal combination therapy using transcatheter arterial infusion of epirubicin and cisplatin, systemic infusion of 5-fluorouracil, and additional percutaneous ethanol injection for unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol 2004;54:415-420. (Pubitemid 39462966)
17. Yamakado K, Nakatsuka A, Akeboshi M, Shiraki K, Nakano T, Takeda K: Combination therapy with radiofrequency ablation and transcatheter chemoembolization for the treatment of hepatocellular carcinoma: short-term recurrences and survival. Oncol Rep 2004;11:105-109.
18. Becker G, Soezgen T, Olschewski M, Laubenberger J, Blum HE, Allgaier HP: Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. World J Gastroenterol 2005;11:6104-6109. (Pubitemid 43085049)
19. Cheng BQ, Jia CQ, Liu CT, Fan W, Wang QL, Zhang ZL, Yi CH: Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. JAMA 2008;299:1669-1677. (Pubitemid 351519864)
20. Zhang L, Fan WJ, Huang JH, Li CX, Zhao M, Wang LG, Tang T: Comprehensive sequential interventional therapy for hepatocellular carcinoma. Chin Med J (Engl) 2009;122:2292-2298.
21. Seong J: Challenge and hope in radiotherapy of hepatocellular carcinoma. Yonsei Med J 2009;50:601-612.
22. Meng MB, Cui YL, Lu Y, She B, Chen Y, Guan YS, Zhang RM: Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Radiother Oncol 2009;92:184-194.
23. Hsu HC, Chen TY, Chiu KW, Huang EY, Leung SW, Huang YJ, Wang CY: Three-dimensional conformal radiotherapy for the treatment of arteriovenous shunting in patients with hepatocellular carcinoma. Br J Radiol 2007;80:38-42. (Pubitemid 46470246)
24. Kim KM, Kim JH, Park IS, Ko GY, Yoon HK, Sung KB, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ: Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol 2009;24:806-814.
25. Han KH, Seong J, Kim JK, Ahn SH, Lee do Y, Chon CY: Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer 2008;113:995-1003.
26. Lau WY, Lai EC: Salvage surgery following downstaging of unresectable hepatocellular carcinoma - a strategy to increase resectability. Ann Surg Oncol 2007;14:3301-3309. (Pubitemid 350160117)
27. Choi SB, Kim KS, Park YN, Choi JS, Lee WJ, Seong J, Han KH, Lee JT: The efficacy of hepatic resection after neoadjuvant transarterial chemoembolization (TACE) and radiation therapy in hepatocellular carcinoma greater than 5 cm in size. J Korean Med Sci 2009;24:242-247.
28. Poon RT, Borys N: Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer. Expert Opin Pharmacother 2009;10:333-343.
29. Nakajima J, Tanaka M, Matsumoto J, Takeuchi E, Fukami T, Takamoto S: Appraisal of surgical treatment for pulmonary metastasis from hepatocellular carcinoma. World J Surg 2005;29:715-718. (Pubitemid 41187530)
30. Kawamura M, Nakajima J, Matsuguma H, Horio H, Miyoshi S, Nakagawa K, Fujisawa T, Kobayashi K: Surgical outcomes for pulmonary metastases from hepatocellular carcinoma. Eur J Cardiothorac Surg 2008;34:196-199.
31. Kwon JB, Park K, Kim YD, Seo JH, Moon SW, Cho DG, Kim YW, Kim DG, Yoon SK, Lim HW: Clinical outcome after pulmonary metastasectomy from primary hepatocellular carcinoma: analysis of prognostic factors. World J Gastroenterol 2008;14:5717-5722.
32. Lee CY, Bae MK, Park IK, Kim DJ, Lee JG, Choi JS, Han KH, Chung KY: Surgical resection for pulmonary metastasis from hepatocellular carcinoma: analysis of prognosis in relation to primary control. J Surg Oncol 2010;101:239-243.
33. Yoon YS, Kim HK, Kim J, Choi YS, Shim YM, Paik SW, Kim K: Long-term survival and prognostic factors after pulmonary metastasectomy in hepatocellular carcinoma. Ann Surg Oncol 2010;17:2795-2801.
34. Seong J, Koom WS, Park HC: Radiotherapy for painful bone metastases from hepatocellular carcinoma. Liver Int 2005;25:261-265.
35. He J, Zeng ZC, Tang ZY, Fan J, Zhou J, Zeng MS, Wang JH, Sun J, Chen B, Yang P, Pan BS: Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy. Cancer 2009;115:2710-2720.
36. Kim JH, Park JW, Kim TH, Koh DW, Lee WJ, Kim CM: Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2007;69:813-819. (Pubitemid 47418391)
37. Hirooka M, Ishida K, Kisaka Y, Uehara T, Watanabe Y, Hiasa Y, Michitaka K, Onji M: Efficacy of splenectomy for hypersplenic patients with advanced hepatocellular carcinoma. Hepatol Res 2008;38:1172-1177.
38. Hidaka H, Kokubu S, Nakazawa T, Minamino T, Takada J, Tanaka Y, Okuwaki Y, Watanabe M, Shibuya A, Saigenji K: Therapeutic benefits of partial splenic embolization for thrombocytopenia in hepatocellular carcinoma patients treated with radiofrequency ablation. Hepatol Res 2009;39:772-778.
39. Huang JH, Gao F, Gu YK, Li WQ, Lu LW: Combined treatment of hepatocellular carcinoma with partial splenic embolization and transcatheter hepatic arterial chemoembolization. World J Gastroenterol 2007;13:6593-6597.
40. Plauth M, Cabre E, Riggio O, Assis-Camilo M, Pirlich M, Kondrup J, Ferenci P, Holm E, Vom Dahl S, Muller MJ, Nolte W: ESPEN guidelines on enteral nutrition: liver disease. Clin Nutr 2006;25:285-294.